Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04445337 · ClinicalTrials.gov registry record · Phase 1
Stellate Ganglion Blockade in Corona Virus 2019 (COVID-19) Positive Patients
A Phase 1 study, sponsored by University of Nebraska.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT04445337: Clinical Trial Phase 1 study, sponsored by University of Nebraska.
NCT04445337 is a Phase 1 study that was terminated before completion, run by University of Nebraska. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04445337, a Phase 1 study, was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study will establish the safety and efficacy of using stellate ganglion blocks in patients with acute respiratory distress syndrome (ARDS) due to COVID-19 disease.
Primary Outcome
a) differences in mean/median values for SGB vs standard of care (SOC) will be assessed at each of the study designated time points for all the continuous biomarker measures - by assessing magnitude of difference and its 95% confidence level and testing differences for statistical significance at each of the time points;
Interventions
- DRUG Stellate Ganglion Block
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-11-15 |
| Est. Completion | 2021-11-01 |
| Phase | Phase 1 |
Why NCT04445337 stopped before completion
NCT04445337 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Stellate Ganglion Block is the first listed.
NCT04445337 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04445337 about?
NCT04445337 is a clinical study titled "Stellate Ganglion Blockade in Corona Virus 2019 (COVID-19) Positive Patients". This study will establish the safety and efficacy of using stellate ganglion blocks in patients with acute respiratory distress syndrome (ARDS) due to COVID-19 disease.
What is the current status of trial NCT04445337?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2020-11-15. Estimated completion is 2021-11-01.
What interventions are being tested in trial NCT04445337?
The interventions under investigation include: Stellate Ganglion Block (DRUG).
Who is sponsoring clinical trial NCT04445337?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04445337's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI